Trial Profile
Therapy of chronic lymphocytic leukemia with dasatinib (BMS-354825)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic lymphocytic leukaemia; T-cell prolymphocytic leukaemia
- Focus Therapeutic Use
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2011 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 07 Apr 2011 Planned end date changed from 1 Aug 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.